Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
Takeda announced that the company plans to grow its vaccines business. CEO Christophe Weber discussed this today in an interview at Reuters Events’ Pharma Japan 2021 conference.
This week, the mRNA leader followed up its announcement of a collaboration with the Institute for Life Changing Medicines (ILCM), with an update on several programs advancing in its pipeline.
Replicate focuses on using self-replicating RNA (srRNA) to develop therapies for autoimmune and inflammatory diseases and prevent drug resistance in cancer.
Heading into fall, with the COVID-19 pandemic surging again and researchers tracking new variants, there’s plenty of news. Here’s a look.
Belgium researchers compared the Moderna and Pfizer-BioNTech COVID-19 vaccines and found that the Moderna jabs generated twice the antibodies than the Pfizer-BioNTech vaccine.
Today, activists with the AIDS Healthcare Foundation are setting up to protest in front of Moderna’s Cambridge headquarters.
The research underlines the progress being made in messenger RNA approaches, as spotlighted by the success of the mRNA vaccines against COVID-19.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu.
JOBS
  • 2025 Hotbed Maps - Genetown - Elite - Moderna.png
IN THE PRESS